Dronedarone Hydrochloride is Used for the management and treatment of atrial fibrillation in patients with risk factors such as coronary heart disease. It was first introduced by Sanofi Aventis Us Llc in its drug Multaq on Jul 1, 2009. 2 different companies have introduced drugs containing Dronedarone Hydrochloride.

Dronedarone Hydrochloride Patents

Given below is the list of patents protecting Dronedarone Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Multaq	US8602215	Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation	Jun 30, 2031	Sanofi Aventis Us
Multaq	US8410167	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality	Apr 16, 2029	Sanofi Aventis Us
Multaq	US9107900	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality	Apr 16, 2029	Sanofi Aventis Us
Multaq	US7323493	Solid pharmaceutical composition containing benzofuran derivatives	Jun 19, 2018 (Expired)	Sanofi Aventis Us
Multaq	US8318800	Solid pharmaceutical compositions containing benzofuran derivatives	Jun 19, 2018 (Expired)	Sanofi Aventis Us
Multaq	US5223510	Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them	Jul 26, 2016 (Expired)	Sanofi Aventis Us

Add above patents to watchlist

Dronedarone Hydrochloride's Family Patents

Full family tree

Dronedarone Hydrochloride Generic API Manufacturers

Only one generic application has been filed for Dronedarone Hydrochloride.

Given below is the list of companies who have filed for Dronedarone Hydrochloride generic, along with the locations of their manufacturing plants worldwide.